PMID- 35281571
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230626
IS  - 1178-6973 (Print)
IS  - 1178-6973 (Electronic)
IS  - 1178-6973 (Linking)
VI  - 15
DP  - 2022
TI  - The Potential Predictive Role of Tumour Necrosis Factor-alpha, Interleukin-1beta, and 
      Monocyte Chemoattractant Protein-1 for COVID-19 Patients Survival.
PG  - 821-829
LID - 10.2147/IDR.S348392 [doi]
AB  - BACKGROUND: Tumour necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), and 
      monocyte chemoattractant protein-1 (MCP-1) are early phase cytokines often 
      encountered when the body is exposed to severe acute respiratory 
      syndrome-associated-coronavirus-2. TNF-alpha, IL-1beta, and MCP-1 are pro-inflammatory 
      cytokines critical in the defence response against systemic infection and injury. 
      Therefore, TNF-alpha, IL-1beta, and MCP-1 are the most aggressive responses to viral 
      infections in the acute phase, so they can be used to determine the survival of 
      coronavirus disease 2019 (COVID-19) patients. PURPOSE: The study aimed to 
      determine the levels of TNF-alpha, IL-1beta, and MCP-1 as predictors of survival for 
      COVID-19 patients. PATIENTS AND METHODS: A prospective cohort study was conducted 
      on confirmed COVID-19 by a reverse-transcriptase-polymerase-chain-reaction 
      (RT-PCR) in 84 adults admitted to the hospital in Indonesia. TNF-alpha, IL-1beta, and 
      MCP-1 level were measured from serum subjects using the enzyme-linked 
      immunosorbent assay. RESULTS: The results from logistic regression modelling of 
      the survival status of COVID-19 patients based on TNF-alpha, IL-1beta, and MCP-1 levels 
      were significant (p-value=0.024). The predictors of all cytokines had P Wald 
      <0.05, so the three cytokines could be used simultaneously to predict the 
      survival status of COVID-19 patients. MCP-1 has the most dominant risk relative 
      value (2.76; 95% CI; 2.53-4.68) compared to TNF-alpha and IL-1beta in predicting patient 
      survival. CONCLUSION: TNF-alpha, IL-1beta, and MCP-1 as markers of acute systemic 
      inflammatory cytokines can be measured at the beginning of hospitalisation of 
      COVID-19 patients for early diagnosis of disease severity so that healthcare 
      professionals can determine clinical guidance needs for therapeutic programs.
CI  - (c) 2022 Kumboyono et al.
FAU - Kumboyono, Kumboyono
AU  - Kumboyono K
AUID- ORCID: 0000-0003-2124-8673
AD  - Nursing Department, Faculty of Health Sciences, University of Brawijaya, Malang, 
      65151, Indonesia.
FAU - Chomsy, Indah Nur
AU  - Chomsy IN
AUID- ORCID: 0000-0002-1050-3571
AD  - Doctoral Program of Medical Science, Faculty of Medicine, University of 
      Brawijaya, Malang, 65145, Indonesia.
FAU - Iskandar, Agustin
AU  - Iskandar A
AD  - Department of Clinical Pathology, Faculty of Medicine, University of Brawijaya, 
      Malang, 65145, Indonesia.
FAU - Aryati, Aryati
AU  - Aryati A
AD  - Department of Clinical Pathology, Faculty of Medicine, Universitas Airlangga, 
      Surabaya, 60131, Indonesia.
FAU - Parwati, Ida
AU  - Parwati I
AD  - Department of Clinical Pathology, Faculty of Medicine, Universitas Padjadjaran, 
      Bandung, 40161, Indonesia.
FAU - Wihastuti, Titin Andri
AU  - Wihastuti TA
AUID- ORCID: 0000-0001-6476-0541
AD  - Basic Nursing Department, Faculty of Health Sciences, University of Brawijaya, 
      Malang, 65151, Indonesia.
LA  - eng
PT  - Journal Article
DEP - 20220304
PL  - New Zealand
TA  - Infect Drug Resist
JT  - Infection and drug resistance
JID - 101550216
EIN - Infect Drug Resist. 2023 Jun 20;16:3943-3944. PMID: 37361934
PMC - PMC8904436
OTO - NOTNLM
OT  - COVID-19
OT  - SARS COV-2
OT  - cytokine
OT  - survival predictors
COIS- The authors report no conflicts of interest in this work.
EDAT- 2022/03/15 06:00
MHDA- 2022/03/15 06:01
PMCR- 2022/03/04
CRDT- 2022/03/14 05:23
PHST- 2021/11/08 00:00 [received]
PHST- 2022/02/21 00:00 [accepted]
PHST- 2022/03/14 05:23 [entrez]
PHST- 2022/03/15 06:00 [pubmed]
PHST- 2022/03/15 06:01 [medline]
PHST- 2022/03/04 00:00 [pmc-release]
AID - 348392 [pii]
AID - 10.2147/IDR.S348392 [doi]
PST - epublish
SO  - Infect Drug Resist. 2022 Mar 4;15:821-829. doi: 10.2147/IDR.S348392. eCollection 
      2022.